TruGraf Contracted With Humana for In-network Coverage of Medicare Kidney Transplant Patients
07 Juillet 2021 - 6:00PM
Business Wire
Eurofins Transplant Genomics,
Inc. (“TGI”), the transplant rejection diagnostics company
committed to improving organ transplant outcomes worldwide, is
excited to announce the first national in-network contract for
TruGraf, its proprietary gene expression test for subclinical acute
rejection. Humana, a leading health care company that offers a wide
range of insurance products and health and wellness services, will
offer in-network coverage for the TruGraf blood gene expression
test to its Medicare kidney transplant patients, effective August
1, 2021.
TruGraf is the first blood
gene expression test approved by CMS/Medicare. TruGraf offers the
earliest possible detection of "silent" subclinical acute rejection
in kidney transplant patients with stable kidney function before
organ injury and chronic acute rejection begins. This novel
biomarker test offers transplant patients a non-invasive option for
otherwise painful biopsy procedures, leading to detection of
subclinical rejection, better long-term outcomes, and an improved
quality of life.
Humana will cover the TruGraf
test for its Medicare Advantage, Medicare HMO, Medicare Network
PFFS, Medicare POS, and Medicare PPO patients.
TGI is very pleased that
Humana has extended in-network coverage for TruGraf, making this
test available to its Medicare transplant patient population. TGI
is committed to working in partnership with medical providers to
make our non-invasive approach to improving transplant outcomes
available to patients who can benefit from it.
About Transplant Genomics, Inc.
Eurofins Transplant Genomics, Inc. ("TGI") is a personalized
diagnostics company committed to improving organ transplant
outcomes worldwide through innovative tests that detect early signs
of graft injury, differentiate among actionable causes, and enable
the optimization of therapy. Working alongside the transplant
community and within the Eurofins family of companies, TGI is
commercializing a suite of tests enabling diagnoses and prediction
of transplant recipient immune status. Our flagship product is
TruGraf, the only non-invasive blood test approved by CMS that
offers the earliest possible detection of "silent" subclinical
acute rejection in kidney transplant recipients with stable graft
function. Test services are offered through TGI's CLIA laboratory
in Fremont, CA. TGI was acquired by Eurofins Scientific in
2019.
Learn more about Transplant Genomics at https://trugraf.com/ and
about Eurofins Scientific at https://www.eurofins.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005635/en/
For further information: Branden Morris Transplant
Genomics, Inc. brandenmorris@eurofins-tgi.com +1-510-745-4707
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024